Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody
- 1 March 2007
- Vol. 62 (3), 276-277
- https://doi.org/10.1136/thx.2004.035519
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.Keywords
This publication has 5 references indexed in Scilit:
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical and Experimental Allergy, 2004
- Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus ConferenceClinical Infectious Diseases, 2003
- Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthmaCurrent Medical Research and Opinion, 2003
- Development of immune responses to Aspergillus at an early age in children with cystic fibrosis.American Journal of Respiratory and Critical Care Medicine, 1994
- Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosisJournal of Allergy and Clinical Immunology, 1992